California State Teachers Retirement System cut its stake in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) by 5.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,028 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. California State Teachers Retirement System owned about 0.14% of BioSpecifics Technologies worth $496,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSTC. Vanguard Group Inc. grew its position in BioSpecifics Technologies by 1.0% during the first quarter. Vanguard Group Inc. now owns 197,424 shares of the biopharmaceutical company’s stock valued at $10,819,000 after purchasing an additional 1,879 shares in the last quarter. Geode Capital Management LLC lifted its stake in BioSpecifics Technologies by 16.7% in the first quarter. Geode Capital Management LLC now owns 66,059 shares of the biopharmaceutical company’s stock valued at $3,619,000 after acquiring an additional 9,462 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in BioSpecifics Technologies by 7.8% in the first quarter. Dimensional Fund Advisors LP now owns 247,114 shares of the biopharmaceutical company’s stock valued at $13,541,000 after acquiring an additional 17,774 shares during the last quarter. Bank of America Corp DE lifted its stake in BioSpecifics Technologies by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 1,371 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its stake in BioSpecifics Technologies by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock valued at $201,000 after acquiring an additional 513 shares during the last quarter. 55.18% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioSpecifics Technologies Corp (NASDAQ BSTC) opened at $43.32 on Thursday. The stock has a market cap of $320.28, a P/E ratio of 28.02 and a beta of 1.58. BioSpecifics Technologies Corp has a one year low of $41.95 and a one year high of $58.79.

BioSpecifics Technologies (NASDAQ:BSTC) last posted its earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.01. The firm had revenue of $6.52 million during the quarter, compared to analysts’ expectations of $6.59 million. BioSpecifics Technologies had a net margin of 42.40% and a return on equity of 19.11%. equities research analysts expect that BioSpecifics Technologies Corp will post 1.57 EPS for the current fiscal year.

A number of analysts have issued reports on BSTC shares. Zacks Investment Research upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $65.00 target price (down from $72.00) on shares of BioSpecifics Technologies in a research note on Monday, November 13th. reduced their target price on shares of BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th. Finally, BidaskClub cut shares of BioSpecifics Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, August 18th.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://theolympiareport.com/2017/12/07/biospecifics-technologies-corp-bstc-shares-sold-by-california-state-teachers-retirement-system.html.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.